

**INTERNATIONAL JOURNAL OF
SPORT NUTRITION AND
EXERCISE METABOLISM**

**New Zealand Blackcurrant Increases Post-Exercise
Hypotension Following Sustained Moderate Intensity
Exercise**

Journal:	<i>International Journal of Sport Nutrition & Exercise Metabolism</i>
Manuscript ID	IJSNEM.2023-0014.R1
Manuscript Type:	Original Research
Keywords:	New Zealand blackcurrant, anthocyanins, post exercise hypotension, heart rate variability, fat oxidation

SCHOLARONE™
Manuscripts

1 ABSTRACT

2 **Previous observations demonstrate** New Zealand blackcurrant (NZBC) extract to alter
3 cardiovascular **responses** at rest without prior exercise. However, the prolonged
4 effects of NZBC on blood pressure and heart rate variability (HRV) following
5 exercise are not known. Participants (*n*15 [5 women], age:31±9 yrs, VO_{2max} : 44±9
6 mL·kg⁻¹·min⁻¹) undertook a control condition of 2-hours of laying supine rest.
7 Subsequently, in a double-blind, placebo controlled, randomised cross-over design
8 participants completed 1-hour of treadmill exercise at 50% VO_{2max} followed by 2-
9 hour supine rest with blood pressure and HRV measurement following a 7-day intake
10 of NZBC and placebo (PLA). With NZBC, there was an increase in average fat
11 oxidation (NZBC: 0.24±0.11 vs. PLA: 0.17±0.11 g·min⁻¹, *P*=0.005), and **larger** high
12 frequency relative power during the exercise (***P*=0.037**). In the 2-hour rest period,
13 delta change for systolic pressure was larger with NZBC than placebo (Control vs
14 NZBC: -5.6±6.4, Control vs PLA: -3.5±6.0 mmHg, *P*=0.033), but was not different
15 for diastolic or mean arterial pressure. There were no alterations in HRV variabilities
16 during the 2-hours following the exercise with NZBC. A 7-day intake of NZBC
17 causes a larger post-exercise hypotension response in young, physically active men
18 and women following 1-hour of treadmill exercise at 50% VO_{2max} .

19

20 **KEYWORDS:** New Zealand blackcurrant; anthocyanins; post exercise hypotension;
21 heart rate variability; fat oxidation

22

23

24

25

- 26 Abbreviations:
- 27 DBP Diastolic blood pressure
- 28 HRV Heart Rate Variability
- 29 MAP Mean arterial pressure
- 30 NZBC New Zealand Blackcurrant
- 31 PL Placebo
- 32 **PPAR Peroxisome-proliferator activated receptor**
- 33 RER Respiratory Exchange Ratio
- 34 SBP Systolic blood pressure
- 35 VO_{2max} maximal rate of oxygen uptake
- 36 vVO_{2max} Velocity at rate of oxygen uptake

37

38 INTRODUCTION

39 Intake of New Zealand blackcurrant extract (**NZBC**) has been shown to increase
40 exercise performance (Cook et al. 2019; Braakhuis et al. 2020; Willems and Blacker
41 2022) and influence cardiovascular responses before (Willems et al. 2015; Cook et al.
42 2017a) and during exercise (Cook et al. 2017; Cook et al. 2021). **Underpinning**
43 **mechanisms** are likely a combination of vasodilation (Cook et al. 2017b; Cook et al.
44 2021), blood flow (Matsumoto et al. 2005) and increased endothelial nitric oxide
45 synthase (Xu et al. 2004) linked to the antioxidant and anti-inflammatory properties of
46 anthocyanins (Special et al. 2014) and metabolites (Keane et al. 2016).

47

48 **Willems et al (2015) and Cook et al (2017a) demonstrated NZBC increased cardiac**
49 **output and decreased total peripheral resistance at rest without prior exercise in**
50 **trained individuals. Blackcurrant anthocyanins has also been observed to influence**

51 cardiovascular function during exercise. For example, Matsumoto et al. (2005)
52 observed oxygenated haemoglobin in the trapezius to be higher with 2-weeks intake
53 of blackcurrant **compared to** a placebo during 30-minutes of typing. In addition,
54 **maximal voluntary contractions (MVC)** of the trapezius performed 3-minutes
55 following the typing, total haemoglobin was also higher. Furthermore, Cook et al.
56 (2017b) observed a 7-day intake of NZBC increased femoral artery **diameter** during a
57 120-second isometric contraction at 30% **MVC** of the knee extensors, with a
58 concomitant decrease in systolic, diastolic and mean arterial blood pressure. Further
59 observations demonstrate that the increased femoral artery diameter during the
60 isometric contraction following NZBC is dependent upon intake duration, **with no**
61 **change from 1-day, but an increase following 4 and 7-days** (Cook et al. 2021).

62
63 Short-duration, localised cardiovascular effects following exercise with NZBC have
64 also been demonstrated. Following a 7-day intake in rock climbers, Fryer et al. (2020)
65 had participants complete 10 handgrip contractions at ~10% before a **tourniquet**
66 occlusion of the brachial artery. The study observed a 37% reduction in oxygen half-
67 time recovery in the *flexor digitorum profundus* demonstrating enhanced oxidative
68 capacity.

69
70 All these alterations in cardiovascular function, blood flow or oxidative capacity
71 following NZBC intake have been made a few minutes during or following exercise.
72 To the authors knowledge there have been no moderate duration measurements of
73 cardiovascular responses following exercise with NZBC.

74

75 Exercise is associated reducing resting blood pressure. The duration and intensity of
76 exercise are important for eliciting prolonged cardiovascular responses following
77 exercise. For example, post-exercise hypotension (PEH) is clinically **important** due to
78 magnitude of change occurring, **with mean systolic and diastolic pressures decreases**
79 **of 5 and 3 mmHg, respectively**, lasting up to 24 hours (Carpio-Rivera et al. 2016). It
80 is caused by multiple physiological responses, including decreased peripheral
81 resistance, sympathetic activity, stroke volume and beta-androgenic receptors and
82 endothelial modulation (Perrier-Melo et al. 2021). It is possible that the influence of
83 NZBC **induced** vasodilation and blood flow would increase PEH. For example,
84 anthocyanin metabolites have been shown to influence vasoactive properties on
85 vascular smooth cells (Keane et al. 2016) and cause endothelium-dependent
86 relaxation of arteries (Bell et al. 2006).

87
88 Heart rate variability (**HRV**) provides non-invasive analysis on the autonomic
89 influences on the heart. The autonomic nervous system and the relationship between
90 sympathetic and parasympathetic branches and their subsequent contributions to
91 cardiac regulation following exercise with NZBC remain unknown. As sympathetic
92 activity is one mechanism of PEH, it is possible that alterations in blood pressure post
93 exercise by NZBC could be explained by **HRV** changes. **Furthermore, anthocyanins**
94 **may attenuate cardiovascular disease risk through the mechanisms of regulation of**
95 **nuclear receptor peroxisome proliferator-activated receptor gamma (Scazzocchio et**
96 **al. 2011), modulation of nuclear factor-kB (NF-kb) (Stefano et al. 2015) and reducing**
97 **thrombotic risk (Santhakumar et al. 2013). In turn, there may also be effects of**
98 **anthocyanins on HRV due to cardiac sympathovagal balance shift toward**

99 parasympathetic activity due to anthocyanin effects upon the microbiome-gut-brain
100 axis (Zong et al. 2023).

101

102 To the authors knowledge there have been no studies examining the prolonged
103 cardiovascular responses following exercise with supplementation of NZBC.

104 Therefore, this study aimed to examine the blood pressure and HRV responses in
105 physically active men and women following 1-hour of moderate intensity treadmill
106 exercise following NZBC intake. It was hypothesized that there would be a larger
107 decrease in post-exercise blood pressure following intake of NZBC.

108

109 **METHODS**

110 *Study*

111 The study was approved by the University of Worcester College of Business,
112 Psychology and Sport Research ethics panel (CBPS2122007), with procedures
113 conducted in accordance with the ethical principles outlined by the Declaration of
114 Helsinki (World Medical Association, 2013).

115 *Participants*

116 Fifteen physically active normotensive participants (5 women) volunteered and
117 provided written informed consent, with characteristics presented in Table 1.
118 Participants were health screened and were not smokers or used dietary supplements.

119 *Experimental Design*

120 A double blind, placebo controlled, crossover design was used, with participants
121 visiting the air-conditioned laboratory (20°C) four times, at the same time of day.
122 Participants abstained from strenuous exercise for 48-hours, alcohol 24-hours before
123 and products containing caffeine on the testing visit days.

124 During visit one, participants underwent screening and had their height (Harpenden
125 Wall Mounted Stadiometer, UK), body mass (Sartorius scales) and blood pressure
126 (Omron M5-I, Omron Healthcare Ltd, Milton Keynes, UK) measured (Table 1).
127 Subsequently, participants completed an incremental treadmill (HP COSMOS,
128 Groningen, Netherlands) protocol to $11 \text{ km} \cdot \text{h}^{-1}$ with expired gas measurement to
129 determine the linear relationship between running speed and VO_2 . Participants then
130 completed another incremental intensity treadmill protocol to volitional exhaustion to
131 calculate $\text{VO}_{2\text{max}}$. After 20-minutes rest, participants performed a verification square
132 wave protocol, whereby an additional 10% speed added the velocity at $\text{VO}_{2\text{max}}$
133 ($\text{VVO}_{2\text{max}}$). Participants ran at this speed for as long as they could with continuous
134 expired gas measurement (Poole and Jones 2017).

135 In the second visit (control condition), participants rested on a massage plinth for 120-
136 minutes with automated blood pressure measurement on the right arm every 15-
137 minutes.

138 Visits three and four were preceded by taking two 300 mg NZBC (CurraNZ®,
139 Health Currancy Ltd., Surrey, UK) or placebo (microcrystalline cellulose M102)
140 identical capsules for 6-days prior. For the 6-days, participants consumed one capsule
141 in the morning, and one in the evening, both times with food. On the day of testing
142 (i.e., day-7), participants were instructed to consume both capsules together, 2-hours
143 before arriving at the laboratory in the morning. Each NZBC capsule contained 105
144 mg of anthocyanins. Following randomisation, eight participants received the NZBC
145 condition on visit three. During the debrief of visit four, six participants correctly
146 guessed what experimental condition order they received (40%). There was a 14-day
147 washout between the experimental conditions.

148 During visits three and four, participants exercised on a treadmill for 60-minutes at
149 50% $\dot{V}O_{2max}$ with continuous measurement of expired gases (Cortex Metalyzer 3B,
150 Biophysik GmbH, Walter-Köhn-Str. 2d 04356, Leipzig, Germany) and analysis every
151 5-minutes by averaging the last 60s of breath-by-breath data. **Carbohydrate and fat**
152 **oxidation were calculated using the stoichiometric equations by Jeukendrup and**
153 **Wallis (2005).** Rating of perceived exertion (RPE – Borg 6-20) was measured every
154 15-minutes. **Following the exercise, participants rested on a massage plinth for 120-**
155 **minutes,** with measurement of expired gases for the first 30-minutes and blood
156 pressure every 15-minutes. **Participants consumed water *ad libitum*.**

157 ***Incremental Intensity Walking and Running for Oxygen-speed Relationship***

158 The incremental intensity treadmill protocol in visit one **determined** the relationship
159 between oxygen uptake and speed. Participants completed 4-minute stages starting at
160 5 $\text{km}\cdot\text{h}^{-1}$ and increased by 1 $\text{km}\cdot\text{h}^{-1}$ until the treadmill reached 11 $\text{km}\cdot\text{h}^{-1}$ with a **1%**
161 **incline.** Expired gases were averaged for the last 60-seconds of each stage and
162 alongside the $\dot{V}O_{2max}$ and $\dot{V}O_{2max}$, the running speed eliciting 50% $\dot{V}O_{2max}$ **was**
163 **calculated using linear regression.**

164

165 ***Maximal Intensity Treadmill Protocol and Verification of $\dot{V}O_{2max}$***

166 The test commenced at 7 $\text{km}\cdot\text{h}^{-1}$ for women and 8 $\text{km}\cdot\text{h}^{-1}$ for men and increased by 1
167 $\text{km}\cdot\text{h}^{-1}$ every minute until volitional exhaustion. The square wave verification
168 protocol commenced with a 2-minute period at 7 $\text{km}\cdot\text{h}^{-1}$ and then **abruptly increased**
169 to 110% $\dot{V}O_{2max}$. Participants **had** no temporal feedback during the protocols but
170 were verbally encouraged. A 15-breath average was used **for** the highest $\dot{V}O_2$ obtained
171 in both protocols, with the verification stage used to confirm no increase in $\dot{V}O_2$,

172 despite a higher intensity. There was no increase in VO_2 obtained in 14 participants in
173 the verification stage (step: 44 ± 9 vs. verification: $42 \pm 8 \text{ mL} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$, $P=0.011$).

174

175 ***Blood Pressure***

176 Blood pressure was measured in accordance with methods from the British
177 Hypertension Society. Briefly, participants rested **awake, breathing normally** without
178 the use of music, books, or electronic devices on a massage plinth with the back rest
179 angled to 45° . **The** cuff was placed around the upper arm approximately 2 cm above
180 the brachial artery and the artery indicator aligned. Two measurements were taken,
181 and the lowest systolic (SBP) and diastolic (DBP) pressure recorded. Mean arterial
182 pressure (MAP) was calculated by:

$$183 \text{ MAP} = \text{DBP} + [(\text{SBP} - \text{DBP}) \div 3]$$

184 ***Heart Rate Variability***

185 **HRV during exercise and was recorded continuously using Actiheart 4 (CamNtech Ltd,**
186 **Cambridgeshire, UK) and analysed on computer software Kubios HRV Standard 3.4.0**
187 **(Kubios Oy, Kuopio, Finland).** During the 60-minute exercise in visits three and four,
188 HRV was determined from 0-5, 10-15, 25-30, 40-45, and 55-60 minutes. **For** the 120-
189 minute rest, HRV was determined from 0-5, 10-15, 25-30, 40-45, 55-60, 70-75, 85-90,
190 100-105, and 115-120 minutes **to avoid the blood pressure measurement.**

191 The HRV included time-domain variables, frequency-domain variables, and overview
192 variables. The time-domain parameters were the SD of normal N-N intervals (SDNN)
193 and the root mean square difference of successive normal R-R intervals (RMSSD).
194 Frequency-domain parameters were the absolute and relative power of High Frequency
195 (HF, 0.15-0.40Hz) and Low Frequency (LF, 0.04-0.15Hz) band (APHF, RPHF, APLF,
196 RPLF), Total Power (TP) and the ratio of LF to HF (LF/HF). PNS Index, SNS Index,

197 and Stress Index were the overview variables analyzed. Beat correction was set to the
198 medium threshold to filter the ectopic beats. Fast Fourier transformation-based Welch's
199 periodogram was performed to calculate the HRV power spectrum.

200

201 *Statistical Analysis*

202 Statistical analysis was conducted using SPSS 27.0 (IBM SPSS Statistics, Armonk,
203 NY: IBM Corp) and GraphPad 9.4.1 (GraphPad Software, San Diego, CA). Data
204 normality was assessed using Kolmogorov-Smirnov test. Variables were analysed for
205 condition (i.e., NZBC vs. PLA vs. Control), time and interaction effects by a two-way
206 repeated measures ANOVA. Repeated measurements were checked for sphericity
207 using Mauchly's test and if sphericity was violated, Greenhouse-Geisser correction
208 applied. Where differences occurred, subsequent pairwise *post hoc* comparisons were
209 undertaken. Natural logarithm transformation (Ln) was performed on skewed
210 distributed HRV variables before analysis. Delta change (Δ) for the 120-minute
211 average blood pressure changes was also calculated for NZBC and PLA against the
212 control condition. Cohen's *d* effect sizes were calculated (Cohen 1998) with an effect
213 size of <0.2 reported as trivial, 0.2-0.49 as small, 0.5-0.69 as moderate and ≥ 0.8 as
214 large. Data is presented as mean \pm standard deviation.

215

216 **RESULTS**

217 *Metabolic Responses during Exercise and Recovery*

218 Data is analysed from *n*14 due to loss of signal of one participant. Participants
219 exercised on the treadmill at 6.9 ± 1.1 km·h⁻¹. During exercise there was no time,
220 condition, or interaction effects for absolute and relative $\dot{V}O_2$, relative intensity,
221 economy, $\dot{V}CO_2$ and heart rate ($P > 0.05$). Minute ventilation demonstrated a time

222 effect ($P<0.001$), with no condition or interaction effects (Table 2). RPE demonstrated
223 a time effect ($P<0.001$), with no condition or interaction effect.

224

225 Fat oxidation during exercise demonstrated a time ($P=0.003$) and condition effect

226 ($P=0.005$) with no interaction effect ($P=0.755$). Pairwise comparisons indicate

227 differences at 5, ($P=0.050$, $d=0.46$), 10 ($P=0.008$, $d=0.81$) 15 ($P=0.019$, $d=0.82$), 20

228 ($P=0.001$, $d=0.84$), 25 ($P=0.032$, $d=0.56$), 30 ($P=0.007$, $d=0.64$), 35 ($P=0.004$,

229 $d=0.63$), 55 ($P=0.048$, $d=0.68$) and 60 ($P=0.044$, $d=0.50$) minutes where fat oxidation

230 was higher with NZBC. In addition, average fat oxidation for the 60-minutes was

231 higher with NZBC (NZBC: 0.24 ± 0.11 vs. PLA: 0.17 ± 0.11 $\text{g}\cdot\text{min}^{-1}$, $P=0.005$, $d=0.67$),

232 with $n=13$ demonstrating an increase. Carbohydrate oxidation also demonstrated a time

233 ($P=0.002$) and condition effect, ($P=0.028$), with no interaction effect ($P=0.882$).

234 Pairwise comparisons indicated carbohydrate oxidation with NZBC was lower at 20

235 ($P=0.008$, $d=0.34$) and 45 minutes ($P=0.030$, $d=0.29$). Average carbohydrate

236 oxidation was lower with NZBC (NZBC: 1.39 ± 0.42 vs. PLA: 1.50 ± 0.48 $\text{g}\cdot\text{min}^{-1}$,

237 $P=0.027$, $d=0.25$). Correspondingly, RER demonstrated a time ($P<0.001$) and

238 condition effect ($P<0.001$) but no interaction effect ($P=0.134$). The pairwise

239 comparisons indicate differences at 5 ($P=0.029$, $d=0.65$), 10 ($P=0.042$, $d=0.69$), 15

240 ($P=0.048$, $d=0.71$), 20 ($P=0.027$, $d=0.75$), 25 ($P=0.003$, $d=0.89$), 30 ($P=0.029$,

241 $d=0.45$), 35 ($P=0.004$, $d=0.76$) 50 ($P=0.007$, $d=0.013$) and 60 minutes ($P<0.001$,

242 $d=0.74$) (Table 2).

243

244 During the 30-minute recovery, there was no condition or interaction effects ($P>0.05$)

245 for absolute and relative VO_2 , VCO_2 , heart rate, minute ventilation, RER, fat

246 oxidation, carbohydrate oxidation and energy expenditure (**Supplemental Table 1**).

247 Time effects were observed for absolute $\dot{V}O_2$ ($P=0.001$), relative $\dot{V}O_2$ ($P=0.002$),
248 $\dot{V}CO_2$ ($P<0.001$), heart rate ($P<0.001$), RER ($P<0.001$), minute ventilation ($P<0.001$),
249 fat oxidation ($P<0.001$) and carbohydrate oxidation ($P<0.001$).

250

251 *Recovery Blood Pressure Responses*

252 **Resting** before the exercise there was no differences between **conditions for SBP**
253 (Control: 113 ± 11 , NZBC: 115 ± 13 , PLA: 117 ± 12 mmHg, $P>0.05$), DBP (Control:
254 69 ± 7 , NZBC: 72 ± 5 , PLA: 71 ± 6 mmHg, $P>0.05$) and MAP (Control: 84 ± 7 , NZBC:
255 86 ± 6 , PLA: 87 ± 6 mmHg, $P>0.05$).

256

257 **For the** 120-minute blood pressure **measurements**, systolic blood pressure demonstrated
258 a time ($P=0.002$), condition ($P=0.002$) and interaction effect ($P=0.040$). At 60-minutes,
259 control was different to NZBC ($P<0.001$, $d=0.62$) and placebo ($P=0.030$, $d=0.26$), **with**
260 NZBC also lower than placebo ($P<0.001$, $d=0.34$). At 75-minutes, control was different
261 to NZBC ($P<0.001$, $d=0.66$) and placebo ($P=0.033$, $d=0.47$). At 90-minutes, control
262 was different to NZBC ($P<0.001$, $d=0.94$). At 105-minutes, control was different to
263 NZBC ($P=0.002$, $d=0.79$) and placebo ($P<0.001$, $d=0.69$). At 120-minutes, control was
264 different to NZBC ($P=0.010$, $d=0.63$). Delta change for systolic pressure was larger
265 following NZBC than placebo (Control vs NZBC: -5.6 ± 6.4 , Control vs PLA: -3.5 ± 6.0
266 mmHg, $P=0.033$, $d=0.34$).

267

268 Diastolic blood pressure was not different for the conditions ($P>0.05$) but was different
269 across time ($P=0.008$) with no interaction effect ($P>0.05$). There was also no difference
270 in delta change for diastolic pressure (Control vs NZBC: -1.6 ± 5.1 , Control vs PLA: $-$
271 0.3 ± 7.0 mmHg, $P=0.119$). Mean arterial pressure demonstrated no condition effect

272 ($P>0.05$) but did have a time effect ($P<0.001$) and an interaction effect ($P=0.043$). At
273 75-minutes, there a was a difference between the conditions ($P=0.017$), with NZBC
274 lower than the control condition ($P=0.010$, $d=0.57$) and the placebo ($P=0.044$, $d=0.36$).
275 At 90-minutes there a was a difference between the conditions ($P=0.022$) with NZBC
276 lower than the control ($P=0.007$, $d=0.69$). At 120-minutes there was a strong trend for
277 a difference between the conditions ($P=0.054$), with NZBC lower than control
278 ($P=0.039$, $d=0.58$). Delta change had a trend to be different between the conditions
279 (Control vs NZBC: -2.7 ± 4.6 , Control vs PLA: -0.9 ± 5.7 mmHg, $P=0.052$, $d=0.36$).

280

281 *Heart Rate Variability*

282 During exercise high frequency relative power was different between NZBC and
283 placebo (Table 3) ($P=0.037$), with high frequency relative power larger following
284 NZBC than PLA at 40-45 minutes ($P=0.030$, $d=1.10$). There were responses over
285 time for all variables, ($P<0.05$), however, there was no interactions ($P>0.05$).

286 *Analysed data is from n10 due to signal loss from five participants.*

287

288 During the *recovery period*, there was a time response for all the HRV variables
289 ($P<0.05$), except the low frequency relative power ($P=0.217$) (Supplemental Table 2).

290 There was no effect condition or interaction effects or for all frequency-domain, time-
291 domain, and overview variables ($P>0.05$). *Analysed data is from n10 due to signal
292 loss from four participants.*

293

294 **DISCUSSION**

295 This study observed that blood pressure decrements after 60-minutes of treadmill
296 exercise at 50% VO_{2max} were larger following 7-days of intake of New Zealand

297 Blackcurrant extract in comparison to placebo in healthy, physically active men and
298 women. This was also observed alongside an increase in fat oxidation and decrease in
299 carbohydrate oxidation during the 60-minutes of exercise.

300

301 *Fat Oxidation*

302 The increase in fat oxidation during exercise following NZBC in the present study
303 supports previous observations (Cook et al. 2015; Cook et al. 2017c; Stauss et al.
304 2018; Hiles et al. 2020; Şahin et al. 2021; Şahin et al. 2022; Willems et al. 2022). This
305 study observed an increase in the average fat oxidation of 0.07 g·min⁻¹ following
306 NZBC which is similar in absolute increases found by Hiles et al. (2020) of 0.12
307 g·min⁻¹, Cook et al. (2015) 0.05 g·min⁻¹ and Cook et al. (2017) 0.11 g·min⁻¹. The
308 increase in fat oxidation observed in this study was completed in untrained men and
309 women during treadmill exercise at 50% VO_{2max} and builds upon previous
310 observations that have used trained individuals, where **there** would be expected
311 adaptations to increase fat oxidation during exercise. **The mechanisms for the altered**
312 **substrate utilisation are not fully known, however, it is possible the blackcurrant**
313 **anthocyanins may have effects upon fat metabolism. For example, blackcurrant**
314 **anthocyanins have been shown to increase mRNA of genes involved with energy**
315 **expenditure including peroxisome proliferator-activated receptor alpha (PPAR) in**
316 **C57BL/6J mice (Benn et al. 2014).**

317

318 The increase in fat oxidation within this study is a strength as it replicates previous
319 findings and demonstrates that the observations of altered blood pressure post-
320 exercise are also likely a result of the NZBC. Furthermore, this study also adds novel
321 **metabolic** observations during the 30-minutes following exercise. Interestingly, the

322 **metabolic changes observed** during exercise with NZBC is not continued during the
323 immediate recovery. The relative VO_2 and RER demonstrated time responses within
324 the 30-minute recovery, with both decreasing following the exercise. This is similar to
325 Kuo et al. (2005); however, they demonstrated that the downward trend for RER
326 plateaus at 60-180 minutes following moderate intensity exercise with values lower
327 than before the exercise. Therefore, it is possible that changes with NZBC may be
328 observed at a later duration, rather than during the first 30-minutes of recovery. A
329 limitation to the present study is also that pre-exercise RER was not measured, as a
330 result, the pre to post exercise comparisons in RER and fat oxidation cannot be made.

331

332 *Blood Pressure Responses and Heart Rate Variability*

333 To the authors knowledge, this is the first study to demonstrate a larger decrease in
334 blood pressure with NZBC in comparison to placebo following exercise. It also
335 supports previous observations of alterations in cardiovascular function with NZBC
336 (Willems et al. 2015; Cook et al. 2017a).

337

338 A key consideration when interpreting the findings from this study is that
339 comparisons of post exercise blood pressure were compared to a control condition of
340 no exercise (Figure 1). With the blood pressure measurements following exercise in
341 the NZBC and placebo conditions, there are lots of degrees of freedom, but also
342 comparisons under different conditions, such as rest without prior exercise and rest
343 following exercise. Including a control condition is a strength as it indicates the
344 exercise was sufficient to elicit post exercise hypotension. Furthermore, it also
345 demonstrates that NZBC increases the extent of post-exercise hypotension beyond the
346 post-exercise hypotension observed following the placebo.

347

348 This study measured resting blood pressure in all visits, with the placebo and NZBC
349 measurement made before the exercise. This is another strength as it provided
350 refamiliarisation and also demonstrated that there was no difference in resting blood
351 pressure between the conditions. This was an important measure as post-exercise
352 blood pressure is influenced by the pre-exercise value, where an inflated pre-value
353 could overestimate the extent of post-exercise hypotension (Carpio-Rivera et al.
354 2016). Therefore, this gives further demonstration of post-exercise hypotension.

355

356 In the present study, NZBC decreased systolic blood pressure by 5.6 mmHg in the 2-
357 hours following exercise. This is clinically relevant because a reduction of 3 mmHg in
358 systolic pressure is associated with a 5% reduction in mortality due to cardiovascular
359 disease (Whelton et al. 2002). Furthermore, it is similar to the 5.3 mmHg systolic
360 pressure decrease observed 6-hours following moderate-intensity aerobic exercise in
361 obese individuals by de Lima Bezerra et al (2019) following beetroot juice intake.

362

363 Future research should examine the post-exercise hypotension response with NZBC
364 to identify mechanisms for the response. *In vitro* studies have demonstrated that the
365 anthocyanin cyanidin-3-glucoside can increase the gene expression of nitric oxide
366 synthase (Xu et al. 2004) and enter vascular endothelia smooth cells (Ziberna et al.
367 2012). In addition, using anthocyanin metabolites *in vitro* have also shown migration
368 of vascular smooth cells (Keane et al. 2016). Therefore, it is possible that the
369 anthocyanins from the NZBC increased nitric oxide availability and it turn,
370 vasorelaxation of peripheral arteries.

371

372 The observations from the HRV, however, do not indicate blood pressure changes
373 were caused by alterations in cardiovascular activity (Table 5). To the authors
374 knowledge, this is the first study to measure HRV following NZBC intake. This was
375 completed during exercise and immediately post at rest, and this study found high
376 frequency relative power during exercise with NZBC was **larger** (Table 3), and low
377 frequency relative power not to change over time during recovery, **regardless of**
378 **condition (Supplement Table 2)**. Changes in the high frequency band during exercise
379 would suggest alterations in the parasympathetic nervous system. The increase in this
380 study could not solely be interpreted by the increased activation of the
381 **parasympathetic** nervous system as it can also be influenced by respiratory behaviour
382 (Bae et al. 2021). Furthermore, this study did not observe any changes in RMSSD
383 alongside the high frequency changes, which would have suggested a vagally
384 mediated change in HRV (Shaffer et al. 2017). Future studies should therefore
385 examine the relationship of NZBC, breathing frequency and **HRV**.

386

387 ***Limitations***

388 Recovery was performed in a seated position on a massage plinth, which is an
389 uncommon method to recover from exercise. Therefore, future research is needed to
390 examine the effects of NZBC on post-exercise hypotension in free-living conditions.
391 Furthermore, blood pressure was recorded in this study for 120-minutes following the
392 exercise and the longer-term effects are not known. For example, reductions in blood
393 pressure have been observed 12.7 hours following exercise in hypertensive
394 individuals (Pescatello et al. 1991) and it is not known if the effects of NZBC on post-
395 exercise hypotension extend to this duration. **Furthermore, future experiments**
396 **examining cardiovascular responses with NZBC should use dietary control, because it**

397 cannot be ruled out that alterations in nitrate (Bailey et al. 2009) or sodium intake
398 influenced blood pressure (Huang et al. 2020).

399

400 ***Conclusions***

401 A 7-day intake of New Zealand Blackcurrant extract increased post-exercise
402 hypotension in comparison to a placebo in the 120-minutes following 60-minutes of
403 treadmill exercise at 50%VO_{2max} in physically active men and women. There was also
404 an increase in fat oxidation and decrease in carbohydrate oxidation rate during the
405 exercise, however there was no effect in the immediate 30-minute recovery. There
406 was larger high frequency relative power during exercise with New Zealand
407 Blackcurrant but no effect upon heart rate variability during the recovery.

408

409 ***Author contributions***

410 MDC conceived and planned the experiments. YS and RW carried out the
411 experiments. MDC and YS undertook data analysis. MDC and YS wrote the
412 manuscript.

413

414 ***Acknowledgement***

415 Supply of supplement (CurraNZ™) for this study was obtained from Health Currancy
416 Ltd (United Kingdom) but had no role in any aspect of the study and manuscript.
417 Experiments were performed in the School of Sport and Exercise Science at the
418 University of Worcester (UK). YS and Ruiqi Wang (RW) were supported for this
419 study by the China Scholarship Council. The authors would like to acknowledge RW
420 for assistance in data collection.

421

422 **Data Availability**

423 Data is available for research purpose upon reasonable request to the corresponding
424 author.

425 **Conflict of interest**

426 The authors report there are no competing interests to declare.

427

428 **REFERENCES**

- 429 1. Bae, D., Matthews, J. J. L., Chen, J. J., Mah, L. (2021). Increased exhalation
430 to inhalation ratio during breathing enhances high-frequency heart rate
431 variability in healthy adults. *Psychophysiology*, 58(11), e13905.
- 432 2. Bailey, S.J., Winyard, P., Vanhatalo, A., Blackwell, J.R., Dimenna, F.J.,
433 Wilkerson, D.P., Tarr, J., Benjamin, N., Jones, A.M. (2009). Dietary nitrate
434 supplementation reduces the O₂ cost of low-intensity exercise and enhances
435 tolerance to high-intensity exercise in humans. *Journal of Applied Physiology*,
436 (1985).107(4):1144-55.
- 437 3. Bell, D.R., Gochenaur, K. (2006). Direct vasoactive and vasoprotective
438 properties of anthocyanin-rich extracts. *Journal of Applied Physiology*,
439 100(4):1164-70.
- 440 4. Benn, T., Kim, B., Park, Y.K., Wegner, C.J., Harness, E., Nam, T.G., Kim,
441 D.O., Lee, J.S., Lee, J.Y. (2014) Polyphenol-rich blackcurrant extract prevents
442 inflammation in diet-induced obese mice. *The Journal of Nutritional*
443 *Biochemistry*. 25:1019–1025
- 444 5. Braakhuis, A.J., Somerville, V.X., Hurst, R.D. (2020). The effect of New
445 Zealand blackcurrant on sport performance and related biomarkers: a
446 systematic review and meta-analysis. *Journal of the International Society of*

- 447 *Sports Nutrition*, 27;17(1):25. Erratum in: *Journal of the International Society*
448 *of Sports Nutrition*, (2021) Jan 12;18(1):8.
- 449 6. Carpio-Rivera, E., Moncada-Jimenez, J., Salazar-Rojas, W., Solera-Herrera,
450 A. (2016) Acute effects of exercise on blood pressure: A Meta-analytic
451 investigation. *Arquivos Brasileiros de Cardiologia*, 106: 422–433
- 452 7. Cohen, J. (1998). *Statistical Power Analysis for the Behavioral Sciences*, 2nd
453 ed.; Erlbaum Associates: Hillsdale, MI, USA
- 454 8. Cook, M.D., Dunne, A., Bosworth, M., Willems, M.E.T. (2021). Effect of
455 Intake Duration of Anthocyanin-Rich New Zealand Blackcurrant Extract on
456 Cardiovascular Responses and Femoral Artery Diameter during Sustained
457 Submaximal Isometric Contraction. *Journal of Dietary Supplements*, 11:1-13.
- 458 9. Cook, M.D., Myers, S.D., Blacker, S.D., Willems, M.E. (2015). New Zealand
459 blackcurrant extract improves cycling performance and fat oxidation in
460 cyclists. *European Journal of Applied Physiology*, 115(11):2357-65.
- 461 10. Cook, M.D., Myers, S.D., Gault, M.L., Edwards, V.C., Willems, M.E. (2017a)
462 Cardiovascular function during supine rest in endurance-trained males with
463 New Zealand blackcurrant: a dose-response study. *European Journal of*
464 *Applied Physiology*, 117(2):247-254.
- 465 11. Cook, M.D., Myers, S.D., Gault, M.L., Edwards, V.C., Willems, M.E.T
466 (2017c). Dose effects of New Zealand blackcurrant on substrate oxidation and
467 physiological responses during prolonged cycling. *European Journal of*
468 *Applied Physiology*, 117(6):1207-1216.
- 469 12. Cook, M.D., Myers, S.D., Gault, M.L., Willems, M.E.T (2017b). Blackcurrant
470 Alters Physiological Responses and Femoral Artery Diameter during
471 Sustained Isometric Contraction. *Nutrients*, 29;9(6):556.

- 472 13. Cook, M.D., Willems, M.E.T. (2019). Dietary Anthocyanins: A Review of the
473 Exercise Performance Effects and Related Physiological Responses.
474 *International Journal of Sports Nutrition and Exercise Metabolism*,
475 1;29(3):322-330.
- 476 14. de Lima Bezerra, Á.D., Costa, E.C., Pacheco, D.A., Souza, D.C., Farias-
477 Junior, L.F., Ritti-Dia, R.M., Grigolo, G.B., de Bittencourt Júnior, P.I.H.,
478 Krause. M., Fayh, A.P.T. (2019). Effect of Acute Dietary Nitrate
479 Supplementation on the Post-Exercise Ambulatory Blood Pressure in Obese
480 Males: A Randomized, Controlled, Crossover Trial. *Journal of Sports Science*
481 *and Medicine*, 11;18(1):118-127
- 482 15. Fryer, S., Giles, D., Bird, E., Stone, K., Paterson, C., Baláš, J., Willems,
483 M.E.T., Potter, J.A., Perkins, I.C. (2020) New Zealand blackcurrant extract
484 enhances muscle oxygenation during repeated intermittent forearm muscle
485 contractions in advanced and elite rock climbers. *European Journal of Sport*
486 *Science*, 17:1-9.
- 487 16. Hiles, A.M., Flood, T.R., Lee, B.J., Wheeler, L.E.V., Costello, R., Walker,
488 E.F., Ashdown, K.M., Kuennen, M.R., Willems, M.E.T. (2020). Dietary
489 supplementation with New Zealand blackcurrant extract enhances fat
490 oxidation during submaximal exercise in the heat. *Journal of Science and*
491 *Medicine in Sport*, 23(10):908-912.
- 492 17. Huang, L., Trieu, K., Yoshimura, S., Neal, B., Woodward, M., Campbell,
493 N.R.C., Li, Q., Lackland, D.T., Leung, A.A., Anderson, C.A.M., MacGregor,
494 G.A., He, F.J. (2020) Effect of dose and duration of reduction in dietary
495 sodium on blood pressure levels: systematic review and meta-analysis of
496 randomised trials. *The British Medical Journal*. 24;368:m315.

- 497 18. Jeukendrup, A.E., Wallis, G.A. (2005). Measurement of substrate oxidation
498 during exercise by means of gas exchange measurements. *International*
499 *Journal of Sports Medicine*. 2005;26 Suppl 1:S28-37.
- 500 19. Keane, K.M., Bell, P.G., Lodge, J.K., Constantinou, C.L., Jenkinson, S.E.,
501 Bass, R., Howatson, G. (2016). Phytochemical uptake following human
502 consumption of Montmorency tart cherry (*L. Prunus cerasus*) and influence of
503 phenolic acids on vascular smooth muscle cells in vitro. *European Journal of*
504 *Nutrition*, 55(4):1695-705.
- 505 20. Kuo, C.C., Fattor, J.A., Henderson, G.C., Brooks, G.A. (2005). Lipid
506 oxidation in fit young adults during postexercise recovery. *Journal of Applied*
507 *Physiology*, 99(1):349-56.
- 508 21. Matsumoto, H., Takenami, E., Iwasaki-Kurashige, K., Osada, T., Katsumura,
509 T., Hamaoka, T. (2005). Effects of blackcurrant anthocyanin intake on
510 peripheral muscle circulation during typing work in humans. *European*
511 *Journal of Applied Physiology*, 94(1-2):36-45.
- 512 22. Perrier-Melo, R.J., Germano-Soares, A.H., Freitas Brito, A., Vilela Dantas, I.,
513 da Cunha Costa, M. (2021). Post-exercise hypotension in response to high-
514 intensity interval exercise: Potential mechanisms. *Revista Portuguesa de*
515 *Cardiologia (Engl Ed)*, 40(10):797-799.
- 516 23. Pescatello, L.S., Fargo, A.E., Leach, C.N. Jr., Scherzer, H.H. (1991). Short-
517 term effect of dynamic exercise on arterial blood pressure. *Circulation*. 83:
518 1557–1561
- 519 24. Poole, D.C., Jones, A.M (2017). Measurement of the maximum oxygen uptake
520 VO₂max: VO₂peak is no longer acceptable. *Journal of Applied Physiology*,
521 122: 997-1002.

- 522 25. Şahin, M.A., Bilgiç, P., Montanari, S., Willems, M.E.T. (2021). Intake
523 Duration of Anthocyanin-Rich New Zealand Blackcurrant Extract Affects
524 Metabolic Responses during Moderate Intensity Walking Exercise in Adult
525 Males. *Journal of Dietary Supplements*, 18(4):406-417.
- 526 26. Şahin, M.A., Bilgiç, P., Montanari, S., Willems, M.E.T. (2022). Daily and Not
527 Every-Other-Day Intake of Anthocyanin-Rich New Zealand Blackcurrant
528 Extract Alters Substrate Oxidation during Moderate-Intensity Walking in
529 Adult Males. *Journal of Dietary Supplements*, 19(1):49-61.
- 530 27. Santhakumar, A.B., Bulmer, A.C., Singh, I. (2014). A review of the
531 mechanisms and effectiveness of dietary polyphenols in reducing oxidative
532 stress and thrombotic risk. *Journal of Human Nutrition and Dietetics*. 27(1):1-
533 21.
- 534 28. Scazzocchio, B., Vari, R., Filesi, C., D'Archivio, M., Santangelo, C.,
535 Giovannini, C., Iacovelli, A., Silecchia, G., Li, Volti G., Galvano, F., Masella,
536 R. (2011). Cyanidin-3-O- β -glucoside and protocatechuic acid exert insulin-
537 like effects by upregulating PPAR γ activity in human omental adipocytes.
538 *Diabetes*, 60(9):2234-44.
- 539 29. Shaffer, F.; Ginsberg, J.P. (2017) An Overview of Heart Rate Variability
540 Metrics and Norms. *Frontiers in Public Health*, 5, 258.
- 541 30. Speciale, A., Cimino, F., Saija, A., Canali, R., Virgili, F. (2014).
542 Bioavailability and molecular activities of anthocyanins as modulators of
543 endothelial function. *Genes & Nutrition*, 9(4), 404.
- 544 31. Strauss, J.A., Willems, M.E.T., Shepherd, S.O (2018). New Zealand
545 blackcurrant extract enhances fat oxidation during prolonged cycling in

- 546 endurance-trained females. *European Journal of Applied Physiology*,
547 118(6):1265-1272.
- 548 32. Vendrame, S., Klimis-Zacas, D. (2015). Anti-inflammatory effect of
549 anthocyanins via modulation of nuclear factor- κ B and mitogen-activated
550 protein kinase signaling cascades. *Nutrition Reviews*. 73(6):348-58.
- 551 33. Whelton, P.K., He, J., Appel, L.J., Cutler, J.A., Havas, S., Kotchen,
552 T.A., Roccella, E.J., Stout, R., Vallbona, C., Winston, M.C., Karimbakas, J.
553 and National High Blood Pressure Education Program Coordinating
554 Committee. (2002) Primary prevention of hypertension: clinical and public
555 health advisory from The National High Blood Pressure Education Program.
556 *The Journal of the American Medical Association*, 288, 1882-1888.
- 557 34. Willems, M.E., Myers, S.D., Gault, M.L., Cook, M.D. (2015). Beneficial
558 Physiological Effects with Blackcurrant Intake in Endurance Athletes.
559 *International Journal of Sport Nutrition and Exercise Metabolism*, 25(4):367-
560 74.
- 561 35. Willems, M.E.T., Banic, M., Cadden, R., Barnett, L. (2022). Enhanced
562 Walking-Induced Fat Oxidation by New Zealand Blackcurrant Extract Is Body
563 Composition-Dependent in Recreationally Active Adult Females. *Nutrients*.
564 14, 1475.
- 565 36. Willems, M.E.T., Blacker, S.D. (2022) Anthocyanin-Rich Supplementation:
566 Emerging Evidence of Strong Potential for Sport and Exercise Nutrition.
567 *Frontiers in Nutrition*, 31; 9:864323.
- 568 37. Xu, J.W., Ikeda, K., Yamori, Y. (2004). Cyanidin-3-glucoside regulates
569 phosphorylation of endothelial nitric oxide synthase. *FEBS Letters*, 10;574(1-
570 3):176-80.

571 38. Zhong, H., Xu, J., Yang, M., Hussain, M., Liu, X., Feng, F., Guan, R. (2023)
572 Protective Effect of Anthocyanins against Neurodegenerative Diseases
573 through the Microbial-Intestinal-Brain Axis: A Critical Review. *Nutrients*.
574 18;15(3):496.

575 39. Ziberna, L., Tramer, F., Moze, S., Vrhovsek, U., Mattivi, F., Passamonti, S.
576 (2012). Transport and bioactivity of cyanidin 3-glucoside into the vascular
577 endothelium. *Free Radical Biology and Medicine*, 1;52(9):1750-9.

578

579

580

581 Figure 1 A Systolic, B Diastolic, C Mean Arterial Pressure in the control condition of
582 no exercise and 120-minutes following exercise with NZBC or placebo. **Data**
583 **presented as mean±SD.** *Control different to NZBC; ‡ Control different to placebo; #
584 NZBC different to placebo.

585

586 Table 1. Participant characteristics

587

588 Table 2. Volume of oxygen uptake and carbon dioxide produced, relative intensity,
589 heart rate, economy, minute ventilation, carbohydrate, and fat oxidation during 60-
590 minutes of treadmill exercise following placebo and New Zealand Blackcurrant
591 extract.

592

593 **Table 3.** Heart rate variability during 60-minutes of treadmill exercise following
594 placebo and New Zealand Blackcurrant extract.

595

596 **Supplement Table 1.** Volume of oxygen uptake and carbon dioxide produced, heart
597 rate, minute ventilation, carbohydrate, and fat oxidation during 30-minutes of rest
598 immediately following 60-minutes of treadmill exercise with placebo and New
599 Zealand Blackcurrant extract.

600

601 **Supplement Table 2.** Heart rate variability during 120-minutes of rest immediately
602 following 60-minutes of treadmill exercise with placebo and New Zealand
603 Blackcurrant extract.

604

For Peer Review

Table 1. Participant characteristics

Age (years)	31±9
Height (cm)	172±10
Body mass (kg)	69±13
VO _{2max} (mL·kg ⁻¹ ·min ⁻¹)	44±9
VO _{2max} (L·min ⁻¹)	3.08±0.84
vVO _{2max} (km·h ⁻¹)	15±3
RER _{max} (AU)	1.20±0.08
HR _{max}	178±11
Resting Systolic Pressure (mmHg)	117±13
Resting Diastolic Pressure (mmHg)	71±8
Resting Mean Arterial Pressure (mmHg)	86±9
Resting Rate Pressure Product	7.03±1.26

Date reported as mean±SD from 15 participants. VO_{2max}: maximal oxygen uptake, vVO_{2max}: running speed on treadmill at maximal oxygen uptake, RER_{max}: Maximum Respiratory Exchange Ratio, HR_{max}: maximum heart rate, AU: arbitrary units.

Table 2. Volume of oxygen uptake and carbon dioxide produced, relative intensity, heart rate, running economy, minute ventilation, carbohydrate, and fat oxidation during 60-minutes of treadmill exercise following placebo and New Zealand Blackcurrant extract.

	Time (min)											
	5	10	15	20	25	30	35	40	45	50	55	60
VO₂ (L·min⁻¹)												
NZBC	1.56±0.45	1.56±0.46	1.56±0.44	1.55±0.43	1.57±0.45	1.57±0.44	1.57±0.44	1.58±0.46	1.56±0.48	1.58±0.44	1.56±0.44	1.56±0.38
Placebo	1.47±0.41	1.49±0.36	1.53±0.38	1.49±0.39	1.49±0.43	1.51±0.42	1.52±0.42	1.53±0.41	1.55±0.38	1.52±0.38	1.54±0.38	01.56±0.38
VO₂ (mL·kg⁻¹·min⁻¹)												
NZBC	22.7±5.0	22.6±5.3	22.7±4.9	22.5±4.8	22.9±5.1	23.1±5.3	22.9±4.9	22.9±5.2	22.6±5.3	22.9±4.9	22.6±4.8	22.6±4.7
Placebo	21.5±5.1	21.7±4.5	22.4±4.6	21.8±4.8	21.6±4.9	22.1±5.0	22.3±5.1	22.4±5.2	22.5±4.6	22.3±4.9	22.5±4.6	22.8±4.8
VCO₂ (L·min⁻¹)												
NZBC	1.44±0.42	1.45±0.44	1.47±0.43	1.45±0.43	1.46±0.43	1.45±0.41	1.44±0.40	1.44±0.41	1.42±0.43	1.44±0.40	1.42±0.40	1.41±0.40
Placebo	1.36±0.42	1.41±0.35	1.45±0.43	1.40±0.37	1.39±0.41	1.40±0.40	1.41±0.38	1.41±0.37	1.41±0.36	1.39±0.34	1.41±0.35	1.40±0.34
Relative intensity (%VO_{2max})												
NZBC	49.3±4.2	49.1±2.7	49.4±3.1	48.9±4.1	49.7±3.9	50.2±3.7	49.7±3.6	49.8±3.9	49.1±3.8	49.8±4.0	49.2±3.8	49.1±3.1
Placebo	46.7±3.9	47.3±2.6	48.6±4.1	47.3±4.0	47.0±3.8	48.0±3.6	48.4±3.9	48.7±3.2	48.9±4.1	48.4±4.1	49.0±3.7	49.5±3.2
Heart Rate (beats·min⁻¹)												
NZBC	123±15	124±14	124±16	124±16	127±18	128±17	130±20	131±21	131±21	132±21	133±21	132±22
Placebo	123±19	125±16	126±16	126±16	127±16	127±16	128±16	129±16	130±17	131±18	132±18	132±19
Economy (mL·kg⁻¹·km⁻¹)												
NZBC	181±40	181±42	182±39	180±39	183±41	185±42	183±40	183±42	181±42	183±37	181±38	181±38
Placebo	171±41	174±42	179±37	174±38	173±39	177±42	178±41	179±39	180±37	180±37	180±38	182±38
VE (L·min⁻¹)[†]												
NZBC	42.0±11.0	44.0±12.6	42.7±10.0	44.0±12.2	45.8±12.7	45.9±13.1	45.9±12.0	45.9±13.5	45.6±13.5	46.4±12.6	46.5±12.7	46.2±12.8
Placebo	42.2±11.4	43.4±10.6	45.0±10.6	44.6±10.4	44.6±12.5	45.4±12.0	45.5±11.5	45.5±11.5	45.1±11.4	45.4±11.1	45.8±11.4	46.5±11.6
Carbohydrate Oxidation (g·min⁻¹)^{†, #}												
NZBC	1.31±0.44	1.50±0.52	1.52±0.44	1.42±0.43*	1.44±0.45	1.41±0.55	1.41±0.52	1.37±0.45	1.33±0.44*	1.35±0.39	1.34±0.42	1.25±0.35
Placebo	1.41±0.44	0.56±0.50	1.62±0.54	1.5.8±0.52	1.57±0.61	1.50±0.50	1.50±0.44	1.48±0.49	1.47±0.51	1.45±0.49	1.44±0.50	1.43±0.52
Fat Oxidation (g·min⁻¹)^{†, #}												
NZBC	0.22±0.11*	0.20±0.10*	0.21±0.10*	0.20±0.08*	0.21±0.10*	0.23±0.11*	0.24±0.12*	0.26±0.15	0.27±0.14	0.28±0.20	0.30±0.16*	0.30±0.19*
Placebo	0.17±0.13	0.11±0.10	0.20±0.08	0.13±0.10	0.15±0.11	0.16±0.09	0.17±0.11	0.20±0.12	0.20±0.13	0.20±0.14	0.20±0.13	0.22±0.12
RER (AU)^{†, #}												
NZBC	0.91±0.04*	0.92±0.04*	0.93±0.04*	0.92±0.05*	0.92±0.03*	0.92±0.04*	0.91±0.03*	0.92±0.04	0.92±0.04	0.91±0.04*	0.91±0.04	0.88±0.04*
Placebo	0.93±0.04	0.95±0.03	0.96±0.05	0.95±0.04	0.95±0.04	0.93±0.04	0.94±0.04	0.92±0.04	0.91±0.04	0.93±0.04	0.91±0.04	0.91±0.05

All measures were collected following 7-days of supplementation with NZBC extract or placebo during treadmill exercise. Data reported as mean±SD from 14 participants, †significant effect for time ($P<0.05$); # significant effect for condition ($P<0.05$); *denotes ($P<0.05$) NZBC vs. placebo. AU: arbitrary units.

For Peer Review

Table 3. Heart rate variability during 60-minutes of treadmill exercise following placebo and New Zealand Blackcurrant extract.

	0-5	10-15	Time (min)			55-60	ANOVA (P)		
			25-30	40-45	Frequency Domain		Condition	Time	Interaction
Frequency Domain									
Low Frequency Relative Power (%)									
NZBC	42.95±14.77	51.84±20.59	55.12±19.24	55.46±18.85	56.38±24.06	0.175	0.003	0.779	
Placebo	45.18±15.39	64.62±13.86	63.13±8.59	65.27±13.48	60.53±19.7				
Low Frequency (Ln)									
NZBC	5.6±1.71	4.24±1.39	3.1±1.35	2.87±1.25	2.71±1.43	0.656	0.000	0.912	
Placebo	5.24±1.48	3.89±1.77	2.98±1.36	2.81±1.48	2.65±1.23				
High Frequency Relative Power (%)									
NZBC	52.85±16.19	40.94±23.15	34.38±21.64	35.3±20.44*	32.79±24	0.037	0.000	0.702	
Placebo	46.26±17.51	25.08±13.44	20.63±11.45	17.81±11.39	26.47±20.43				
High Frequency (Ln)									
NZBC	5.91±1.95	4.05±2.18	2.72±1.78	2.27±1.36	1.87±1.36	0.212	0.000	0.848	
Placebo	5.37±1.7	3±2.11	1.92±1.63	1.64±1.43	1.58±1.21				
Low/High Frequency (Ln)									
NZBC	-0.21±0.68	0.32±1.06	0.63±1.1	0.56±0.97	0.67±1.27	0.063	0.000	0.643	
Placebo	0.01±0.79	1.03±0.7	1.26±0.71	1.45±0.75	0.98±1.19				
Total Power (Ln)									
NZBC	6.5±1.85	4.98±1.73	3.75±1.54	3.44±1.47	3.28±1.43	0.444	0.000	0.899	
Placebo	6.08±1.62	4.35±1.86	3.42±1.39	3.25±1.43	3.08±1.24				
Time Domain									
SDNN (ms)									
NZBC	46.71±32.02	23.88±25.3	12.25±10.48	9.71±6.24	9±4.95	0.341	0.000	0.783	
Placebo	39.53±28.45	15.35±18.8	8.43±5.13	8.08±5.13	7.18±4.27				
RMSSD (ms)									
NZBC	46.83±39.4	31.06±36.33	15.67±17.4	12.16±11.51	10.74±9.3	0.328	0.000	0.811	
Placebo	40.88±38.37	17.22±25.96	8.21±4.64	7.88±4.9	8.1±6.22				
Overview									
Parasympathetic nervous system index									
NZBC	-1.78±1.04	-2.6±1	-3.07±0.74	-3.24±0.54	-3.33±0.49	0.465	0.000	0.659	
Placebo	-1.81±0.92	-3.06±0.77	-3.25±0.49	-3.37±0.51	-3.42±0.61				
Sympathetic nervous system index									
NZBC	5.15±1.8	8.04±2.8	10.04±5.89	10.46±5.26	11.07±5.82	0.627	0.000	0.872	
Placebo	4.73±2.06	8.61±2.55	11.14±6.74	11.96±6.58	12.78±7.13				
Stress Index									
NZBC	16.95±10.48	31.2±16.59	40.92±25.31	42.02±22.01	44.27±24.63	0.489	0.000	0.735	
Placebo	16.76±9.99	32.88±13.54	47.74±28.6	49.98±27.03	52.9±28.36				

All measures were collected following 7-days of supplementation with NZBC extract or placebo during treadmill exercise. Data reported as mean \pm SD from 10 participants. SDNN; Standard Deviation of the NN intervals, RMSSD; square root of the mean of the sum of the squares of differences between adjacent NN intervals. *different between placebo and NZBC (P<0.05).

For Peer Review

Supplement Table 1. Volume of oxygen uptake and carbon dioxide produced, heart rate, minute ventilation, carbohydrate, and fat oxidation during 30-minutes of rest immediately following 60-minutes of treadmill exercise with placebo and New Zealand Blackcurrant extract.

	Time (min)					
Condition	5	10	15	20	25	30
VO_2 ($\text{L} \cdot \text{min}^{-1}$) †						
NZBC	0.32±0.07	0.31±0.08	0.28±0.09	0.30±0.08	0.29±0.06	0.28±0.07
Placebo	0.39±0.10	0.31±0.07	0.30±0.07	0.29±0.08	0.28±0.06	0.28±0.06
VO_2 ($\text{mL} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$) †						
NZBC	4.69±0.90	4.45±0.74	4.11±1.14	4.32±0.93	4.20±0.79	4.03±0.93
Placebo	4.96±1.16	4.43±1.05	4.28±0.93	4.15±0.72	4.00±0.83	3.94±0.78
VCO_2 ($\text{L} \cdot \text{min}^{-1}$) †						
NZBC	0.31±0.07	0.28±0.08	0.25±0.08	0.26±0.07	0.25±0.05	0.24±0.06
Placebo	0.34±0.09	0.29±0.06	0.27±0.07	0.26±0.05	0.24±0.05	0.24±0.05
Heart Rate ($\text{beats} \cdot \text{min}^{-1}$) †						
NZBC	88±34	86±35	82±34	83±36	83±36	80±36
Placebo	84±20	83±21	79±20	81±21	78±22	75±20
VE ($\text{L} \cdot \text{min}^{-1}$) †						
NZBC	13.63±2.65	12.32±2.35	11.17±2.86	11.45±2.73	10.87±2.09	10.36±2.32
Placebo	15.25±3.75	12.87±2.78	12.12±2.72	11.25±1.80	10.36±2.32	10.33±2.08
Carbohydrate Oxidation ($\text{g} \cdot \text{min}^{-1}$) †						
NZBC	0.37±0.09	0.28±0.10	0.23±0.10	0.22±0.10	0.18±0.06	0.19±0.09
Placebo	0.40±0.12	0.29±0.08	0.26±0.10	0.21±0.09	0.19±0.09	0.18±0.07
Fat Oxidation ($\text{g} \cdot \text{min}^{-1}$) †						
NZBC	0.02±0.02	0.05±0.03	0.05±0.02	0.07±0.03	0.07±0.02	0.06±0.06
Placebo	0.02±0.03	0.04±0.02	0.05±0.03	0.07±0.04	0.06±0.03	0.07±0.03
RER (AU) †						
NZBC	0.98±0.07	0.91±0.05	0.89±0.04	0.88±0.05	0.85±0.03	0.87±0.02
Placebo	0.97±0.07	0.93±0.06	0.91±0.07	0.87±0.09	0.87±0.07	0.86±0.06

All measures were collected following 7-days of supplementation with NZBC extract or placebo during 30 minutes of rest following 60 minutes treadmill exercise. Data reported as mean±SD from 14 participants, †significant effect for time ($P<0.05$).

For Peer Review

Supplement Table 2. Heart rate variability during 120-minutes of rest immediately following 60-minutes of treadmill exercise with placebo and New Zealand Blackcurrant extract.

	Time (min)										ANOVA (P)		
	0-5	10-15	25-30	40-45	55-60	70-75	85-90	100-105	115-120		Condition	Time	Interaction
Frequency Domain													
Low Frequency Relative Power (%)													
NZBC	51.25±12.79	45.15±13.43	44.84±17.43	52.19±22.18	55.55±15.65	49.58±18.34	51.43±21.62	53.74±16.93	55.35±16.89				
Placebo	61.14±14.98	58.56±20.08	45.49±16.45	47.53±20.58	54.59±19.39	51.21±18.64	49.79±16.06	53.14±15.34	55.81±19.18	0.764	0.217	0.224	
Low Frequency (Ln)													
NZBC	6.28±0.88	6.55±0.78	6.98±0.9	7.08±0.87	7.16±0.92	7.02±1.01	6.96±0.97	7.29±0.67	7.37±0.51				
Placebo	6.21±1.33	6.94±1.03	6.79±1.05	6.74±0.97	7.29±0.69	7.19±0.69	7.11±0.8	7.36±0.43	7.47±0.73	0.970	0.000	0.667	
High Frequency Relative Power (%)													
NZBC	40.9±13.61	49.59±14.15	49.72±19.49	40.56±23.66	34.12±16.55	41.02±22.02	42.12±24.38	32.68±17.83	36.56±17.43				
Placebo	29.27±14.39	35.28±19.21	47.6±19.65	42.69±22.9	38.36±20.24	36.61±22.84	42.99±16.28	38.04±17.14	37.73±20.46	0.803	0.007	0.091	
High Frequency (Ln)													
NZBC	6.01±1.14	6.62±0.7	7.11±0.8	6.77±0.89	6.61±0.98	6.78±1.02	6.77±1.14	6.7±0.92	6.93±0.85				
Placebo	5.38±1.66	6.34±0.95	6.8±1.08	6.57±1.03	6.87±0.55	6.78±0.74	6.98±0.74	6.97±0.61	7.08±0.74	0.841	0.000	0.428	
Low/High Frequency Ratio (Ln)													
NZBC	0.49±0.97	0.13±0.91	0.13±1.2	0.48±1.23	0.67±0.83	0.37±1.09	0.38±1.42	0.74±1.01	0.56±0.89				
Placebo	0.97±0.87	0.81±1.2	0.19±1.07	0.34±1.18	0.55±1.06	0.55±1.13	0.33±0.96	0.59±1.03	0.49±1.07	0.810	0.036	0.140	
Total Power (Ln)													
NZBC	6.98±0.93	7.38±0.67	7.88±0.69	7.85±0.68	7.79±0.88	7.82±0.87	7.8±0.78	7.96±0.62	8.05±0.55				
Placebo	6.73±1.39	7.54±0.82	7.64±0.93	7.58±0.77	7.97±0.31	7.95±0.46	7.88±0.66	8.05±0.31	8.17±0.49	0.908	0.000	0.678	
Time Domain													
SDNN (ms)													
NZBC	34.34±11.71	45.49±14.7	56.99±19.55	53.12±17.71	53.62±19.63	57.36±22.73	58.81±20.89	61.19±19.47	62.06±16.49				
Placebo	32.13±16.26	46.53±18.16	53.43±23.71	49.19±18.04	56.75±11.7	56.71±13.73	55.93±16.62	58.68±14.6	62.57±16.61	0.820	0.000	0.873	
RMSSD (ms)													
NZBC	31.44±13.94	49.15±22.86	64.16±31.8	56.1±29.11	54.18±24.26	62.23±31.53	62.52±30.31	59.16±25.68	61.06±21.91				
Placebo	27.37±14.61	46.4±21.48	57.29±33.05	51.4±23.4	58.79±15.2	58.55±20.37	61.77±21.16	60.56±21.66	65.04±25.49	0.867	0.000	0.608	
Overview													
Parasympathetic nervous system index													
NZBC	-1.36±0.84	-0.04±1.34	0.65±1.59	0.58±1.52	0.29±1.25	0.93±1.56	0.91±1.45	0.7±1.24	0.87±1.32				
Placebo	-1.7±0.73	-0.23±1.02	0.39±1.47	0.35±1.04	0.77±0.86	0.76±0.98	1.05±0.95	0.96±1.13	1.11±1.14	0.942	0.000	0.198	
Sympathetic nervous system index													
NZBC	2.05±1.32	0.45±1.39	-0.14±1.41	-0.21±1.27	-0.1±1.22	-0.53±1.25	-0.59±1.09	-0.48±0.98	-0.58±1.1				
Placebo	2.71±1.66	0.64±1.52	0.08±1.28	-0.09±0.86	-0.61±0.53	-0.6±0.54	-0.76±0.62	-0.74±0.7	-0.82±0.64	0.933	0.000	0.616	
Stress Index													
NZBC	12.94±3.54	10.08±3.83	8.44±3.78	8.88±3.3	7.75±4.65	7.94±3.55	7.48±2.6	7.61±2.65	7.35±2.4				
Placebo	14.46±5.13	10.83±5.69	9.53±4.3	9.42±3.21	7.47±1.09	7.54±1.3	7.64±1.93	7.36±1.64	6.99±1.5	0.762	0.000	0.773	

All measures were collected following 7-days of supplementation with NZBC extract or placebo following 60-minutes of treadmill exercise. Data reported as mean \pm SD from 10 participants. SDNN; Standard Deviation of the NN intervals, RMSSD; square root of the mean of the sum of the squares of differences between adjacent NN intervals.

For Peer Review




Figure 1 A Systolic, B Diastolic, C Mean Arterial Pressure in the control condition of no exercise and 120-minutes following exercise with NZBC or placebo. Data presented as mean \pm SD. *Control different to NZBC; ‡ Control different to placebo; # NZBC different to placebo.

127x266mm (300 x 300 DPI)